Public Funding for Retendon Limited

The aim of this project is to **develop a novel tendon repair medical device that improves health outcomes in patients with tendon injuries**. Tendon injuries can be severely disabling to patients, often requiring an operation with long rehabilitation times and high healthcare costs. The most common types of tendon injuries that require surgical repair are: Flexor (hand): ~18,000 operations/year in UK Achilles (foot): ~ 62,000 operations/year in UK Rotator cuff (shoulder): ~9,000 operations/year in UK The number of operations per 100,000 people are similar abroad. Up to 1 in 4 tendon operations do not achieve satisfactory results due to the formation of scar tissue that works less well than the original tendon. Between 1 in 20 and 1 in 5 of repaired tendons (dependent on which tendon was broken) can break again requiring further operations. ReTendon has developed a novel tendon repair medical device, which builds a bridge between the ends of sown-together tendons. Our device enables tendons to re-build more naturally, with a potential for tendons to heal faster and more strongly, it also reduces tendons from breaking after operation, reducing reoperation costs and the length of rehabilitation and time off work for patients. Our initial research demonstrates that our device is safe and is likely to improve tendon repair. We have also established manufacturing processes and demonstrated the ability to manufacture a stable and sterile product. This patent-protected work draws on breakthrough UK research at the University of Manchester and will be further developed and commercialised by UK company ReTendon Limited. The aim of this early-stage project is to create the complete technical and commercial data package required to enable ReTendon to obtain follow-on investment and regulatory (MHRA) approval for a first clinical trial in humans. The project partners are ReTendon Ltd (Lead, Proctor) and the University of Manchester (Cartmell), supported by an existing team, expert subcontractors and clinical advisors. This team has the necessary expertise in biology, engineering, industrial and clinical practice to deliver the above project. We anticipate that completion of this project will enable a first in human clinical trial; a successful trial will then enable this platform technology to be adapted for multiple tendon injuries, ligament injuries and has scope for veterinary applications. The project will provide a basis for ReTendon to become a global leader in soft tissue repair, improving patient outcomes and creating commercial impact from novel UK research.